Literature DB >> 29179248

Radical Prostatectomy for Patients With Oligometastatic Prostate Cancer.

Ardalan E Ahmad, Ricardo Leão, Robert J Hamilton.   

Abstract

Cancer progresses in a stepwise fashion. Oligometastatic cancer is an intermediate stage of tumor spread between localized disease and disseminated metastases. Oligometastatic prostate cancer is defined as up to five extrapelvic lesions on conventional imaging. There are controversies surrounding the management of this malignancy, but retrospective and population-based studies suggest a role for radical prostatectomy. Despite insufficient data to draw conclusions regarding the effectiveness of aggressive therapies on overall or cancer-specific survival of patients with oligometastatic prostate cancer, current studies suggest that surgery decreases tumor burden, disease-related morbidity, and the need for palliative surgical intervention, while increasing the period of time to development of castration-resistant disease.

Entities:  

Mesh:

Year:  2017        PMID: 29179248

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  3 in total

1.  Silybin Prevents Prostate Cancer by Inhibited the ALDH1A1 Expression in the Retinol Metabolism Pathway.

Authors:  Ying Jiang; Hanbing Song; Ling Jiang; Yu Qiao; Dan Yang; Donghua Wang; Ji Li
Journal:  Front Cell Dev Biol       Date:  2020-08-31

Review 2.  Imaging modalities in synchronous oligometastatic prostate cancer.

Authors:  Jurgen J Futterer; Cristian Surcel; Roderick van den Bergh; Hendrik Borgmann; Alberto Briganti; Giorgio Gandaglia; Alexander Kretschmer; Piet Ost; Prasanna Sooriakumaran; Derya Tilki; Massimo Valerio; Guillaume Ploussard; Pieter J L De Visschere; Igor Tsaur
Journal:  World J Urol       Date:  2018-08-01       Impact factor: 4.226

3.  Sirtuin 5 regulates the proliferation, invasion and migration of prostate cancer cells through acetyl-CoA acetyltransferase 1.

Authors:  Jingqian Guan; Xizi Jiang; Junda Gai; Xiaodan Sun; Jinming Zhao; Ji Li; Yizhuo Li; Ming Cheng; Tengjiao Du; Lin Fu; Qingchang Li
Journal:  J Cell Mol Med       Date:  2020-10-26       Impact factor: 5.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.